Atrial Fibrillation (AF) is the most frequently diagnosed arrhythmia in population.
Its prevalence increases with age with as many as 8.8% of people older than 80 years are affected.
Stroke is the most feared consequence of AF. Anticoagulation oral therapy with warfarin has been used clinically for many decades. However in recent years the international scenario has significantly changed since of the advent of new oral anticoagulants (NAO): dabigatran, rivaroxaban and apixaban.